|
LIVE WEBINAR: Monday, September 11, 2023, 5:00 PM – 6:00 PM Eastern Time
Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast CancerA CME/MOC-Accredited Live Webinar Register for this complimentary event with the “Register Now” button above, Join us on Monday, September 11th for this CME/MOC-accredited webinar Faculty
Hope S Rugo, MD Professor of Medicine Winterhof Family Professor of Breast Cancer Director Breast Oncology and Clinical Trials Education Medical Director Cancer Infusion Services University of California, San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco, California
Tiffany A Traina, MD, FASCO
Vice Chair, Department of Medicine Section Head Triple-Negative Breast Cancer Clinical Research Program Associate Attending Physician Breast Medicine Service Memorial Sloan Kettering Cancer Center Associate Professor Weill Cornell Medical College New York, New York Moderator Neil Love, MD Research To Practice Miami, Florida Thursday, August 31, 2023 Topics to Be Discussed
Target Audience
CE Credit FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Rugo — Consultancy/Advisory Support: Daiichi Sankyo Inc, Napo Pharmaceuticals Inc, Puma Biotechnology Inc, Viatris; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Pionyr Immunotherapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc, Taiho Oncology Inc, Veru Inc; Travel Support to Academic Meetings: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Merck. Dr Traina — Consulting or Advisory Role: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, G1 Therapeutics Inc, GE Healthcare, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Hengrui Therapeutics Inc, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc, TerSera Therapeutics LLC; Research Funding (to Institution): Astellas, AstraZeneca Pharmaceuticals LP, Ayala Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. SURVEY PARTICIPANTS — Aditya Bardia, MD, MPH — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Phillips HealthCare Services Ltd, Radius Health Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Radius Health Inc, Sanofi. Adam M Brufsky, MD, PhD — Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc, Sanofi, Seagen Inc; Contracted Research: Agendia Inc, AstraZeneca Pharmaceuticals LP. Melinda Telli, MD —Advisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Guardant Health, Immunomedics Inc, Lilly, Merck, Natera Inc, Novartis, Pfizer Inc, RefleXion, Replicate Bioscience, Sanofi; Contracted Research: AbbVie Inc, Bayer HealthCare Pharmaceuticals, Biothera Pharmaceuticals Inc, Calithera Biosciences, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Hummingbird Bioscience, Medivation Inc, a Pfizer Company, Novartis, OncoSec Medical, Pfizer Inc, PharmaMar, Tesaro, A GSK Company, Vertex Pharmaceuticals; Data and Safety Monitoring Board/Committee: G1 Therapeutics Inc, Gilead Sciences Inc. Sara M Tolaney, MD, MPH — Consulting Agreements: 4D Pharma PLC, Aadi Bioscience, ARC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Lilly, Menarini Group, Merck, Myovant Sciences, Novartis, OncoSec Medical, OncXerna Therapeutics Inc, Pfizer Inc, Reveal Genomics, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Umoja Biopharma, Zentalis Pharmaceuticals, Zetagen, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer Inc, Sanofi, Seagen Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Gilead Sciences Inc and Merck. |